Loading...
•
Jun 30
•/
Ascendis Pharma Q2 2025 Earnings Report
Ascendis Pharma reported its second quarter 2025 financial results, highlighting significant revenue growth driven by YORVIPATH and SKYTROFA, alongside progress in its clinical pipeline.
Key Takeaways
Ascendis Pharma delivered strong financial results in Q2 2025, with total revenue reaching €158.0 million, a substantial increase from the previous year, primarily due to the robust performance of YORVIPATH and SKYTROFA. The company also made significant strides in its clinical development, with TransCon CNP under FDA Priority Review and planned label expansions for SKYTROFA.
Total revenue for Q2 2025 was €158.0 million, a significant increase from €36.0 million in Q2 2024.
YORVIPATH revenue reached €103.0 million and SKYTROFA revenue was €50.7 million in Q2 2025.
TransCon CNP's New Drug Application (NDA) is under Priority Review by the U.S. FDA with a PDUFA date of November 30, 2025.
The company reported a net loss of €38.9 million, or €0.64 per basic share, a notable improvement from a €109.4 million net loss in the prior year period.
Ascendis Pharma
Ascendis Pharma
Ascendis Pharma Revenue by Segment
Revenue by Segment
Commercial Products Revenue
CapyFin.comRendering of Services & Clinical Supply Revenue
CapyFin.comLicenses Revenue
CapyFin.comSKYTROFA Revenue
CapyFin.comYORVIPATH Revenue
CapyFin.com Forward Guidance
Ascendis Pharma anticipates continued momentum in its pipeline, with key regulatory milestones and clinical trial initiations expected in 2025, aiming to expand its market presence and address unmet medical needs.
Positive Outlook
- TransCon CNP NDA under Priority Review with PDUFA date of November 30, 2025.
- Expect to submit Marketing Authorisation Application (MAA) for TransCon CNP to EMA during Q3 2025.
- Plan to initiate basket trial for SKYTROFA in several established growth-hormone indications during Q4 2025.
- Plan to submit an IND or similar to investigate TransCon CNP alone and in combination with TransCon hGH for hypochondroplasia during Q4 2025.
- Initiation of a Phase 3 combination trial for TransCon CNP + TransCon hGH expected in Q4 2025.
Challenges Ahead
- No specific negative forward guidance points were explicitly stated in the provided text.
- The company's forward-looking statements involve substantial risks and uncertainties.
- Dependence on third-party manufacturers, distributors, and service providers.
- Unforeseen safety or efficacy results in development programs or on-market products.
- Unforeseen expenses related to commercialization or development programs.
Revenue & Expenses
Visualization of income flow from segment revenue to net income